94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
Yu-Li Shen1,2†Yi-ping Jiang3†Xiao-Qin Li1,4†Su-Juan Wang5Ming-Hua Ma6Chun-Yan Zhang7Jian-Yong Zhu7
Khalid Rahman8Li-Jun Zhang1*
Xin Luan1,2*
Hong Zhang1*- 1Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai, China
- 2Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China
- 3Department of Pharmacognosy, School of Pharmacy, Second Military Medical University, Shanghai, China
- 4School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, China
- 5Department of Drug Preparation, Hospital of TCM and Hui Nationality Medicine, Ningxia Medical University, Wuzhong, China
- 6Department of Pharmacy, Yangpu Hospital, Tongji University School of Medicine, Shanghai, China
- 7Central Laboratory, Seventh People’s Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China
- 8School of Pharmacy and Biomolecular Sciences, Faculty of Science, Liverpool John Moores University, Liverpool, United Kingdom
This article has been retracted. Please follow the link to the full retraction notice for details.
Citation: Shen Y-L, Jiang Y-p, Li X-Q, Wang S-J, Ma M-H, Zhang C-Y, Zhu J-Y, Rahman K, Zhang L-J, Luan X and Zhang H (2021) Corrigendum: ErHuang Formula Improves Renal Fibrosis in Diabetic Nephropathy Rats by Inhibiting CXCL6/JAK/STAT3 Signaling Pathway. Front. Pharmacol. 12:789192. doi: 10.3389/fphar.2021.789192
Received: 22 October 2021; Accepted: 29 October 2021;
Published: 18 November 2021; Retracted: 02 December 2024.
Edited and reviewed by:
Adolfo Andrade-Cetto, National Autonomous University of Mexico, Mexico